LPCN Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of 51.05% compared to Lipocine's net margin of --. Lipocine's return on equity of 0.04% beat Nanoviricides's return on equity of --.

Lipocine has a consensus price target of $6.75, signalling upside risk potential of 124.25%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 501.85%. Given that Nanoviricides has higher upside potential than Lipocine, analysts believe Nanoviricides is more attractive than Lipocine.

Lipocine has a beta of 1.514, which suggesting that the stock is 51.371% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.927, suggesting its less volatile than the S&P 500 by 7.287%.

Lipocine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lipocine pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Lipocine quarterly revenues are $3.5M, which are larger than Nanoviricides quarterly revenues of --. Lipocine's net income of $1.8M is higher than Nanoviricides's net income of -$2M. Notably, Lipocine's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lipocine is 3.89x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of 51.05% compared to Lipocine's net margin of --. Lipocine's return on equity of 0.04% beat Oragenics's return on equity of --.

Lipocine has a consensus price target of $6.75, signalling upside risk potential of 124.25%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 434.19%. Given that Oragenics has higher upside potential than Lipocine, analysts believe Oragenics is more attractive than Lipocine.

Lipocine has a beta of 1.514, which suggesting that the stock is 51.371% more volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

Lipocine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lipocine pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Lipocine quarterly revenues are $3.5M, which are larger than Oragenics quarterly revenues of --. Lipocine's net income of $1.8M is higher than Oragenics's net income of -$3.3M. Notably, Lipocine's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lipocine is 3.89x versus 1.17x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 51.05% compared to Lipocine's net margin of -2357.27%. Lipocine's return on equity of 0.04% beat Palatin Technologies's return on equity of --.

Lipocine has a consensus price target of $6.75, signalling upside risk potential of 124.25%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1268.52%. Given that Palatin Technologies has higher upside potential than Lipocine, analysts believe Palatin Technologies is more attractive than Lipocine.

Lipocine has a beta of 1.514, which suggesting that the stock is 51.371% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Lipocine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lipocine pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Lipocine quarterly revenues are $3.5M, which are larger than Palatin Technologies quarterly revenues of $350K. Lipocine's net income of $1.8M is higher than Palatin Technologies's net income of -$2.4M. Notably, Lipocine's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lipocine is 3.89x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 51.05% compared to Lipocine's net margin of --. Lipocine's return on equity of 0.04% beat Theriva Biologics's return on equity of --.

Lipocine has a consensus price target of $6.75, signalling upside risk potential of 124.25%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 455.56%. Given that Theriva Biologics has higher upside potential than Lipocine, analysts believe Theriva Biologics is more attractive than Lipocine.

Lipocine has a beta of 1.514, which suggesting that the stock is 51.371% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Lipocine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lipocine pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Lipocine quarterly revenues are $3.5M, which are larger than Theriva Biologics quarterly revenues of --. Lipocine's net income of $1.8M is higher than Theriva Biologics's net income of -$4.4M. Notably, Lipocine's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lipocine is 3.89x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.